Publicacions en col·laboració amb investigadors/es de Instituto de Investigación Sanitaria Gregorio Marañón (23)

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

  2. Opioids and fibromyalgia: frequency of use and factors associated with increased consumption in patients remitted to a tertiary care center

    BMC Musculoskeletal Disorders, Vol. 25, Núm. 1

  3. Salivary gland ultrasound features in sicca syndrome secondary to immunotherapy with checkpoint inhibitors

    Clinical Rheumatology

2023

  1. Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey'

    Annals of the Rheumatic Diseases

  2. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  3. Impact of ultrasound limitation to assess aortitis in patients with giant cell arteritis: comparative study with FDG-PET/CT

    RMD open, Vol. 9, Núm. 3

  4. Oral or pulse glucocorticoid use at the onset of giant cell arteritis and its influence on the risk of relapse: a retrospective study

    Rheumatology International, Vol. 43, Núm. 7, pp. 1333-1340

  5. Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care

    RMD open, Vol. 9, Núm. 2

  6. The role of ultrasound and FDG-PET/CT to detect extracranial artery involvement in patients with suspected large vessel vasculitis

    Modern rheumatology, Vol. 33, Núm. 3, pp. 549-556

2022

  1. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy

    RMD Open, Vol. 8, Núm. 1

  2. Impact of cardiovascular risk on the diagnostic accuracy of the ultrasound Halo Score for giant cell arteritis

    Arthritis Research and Therapy, Vol. 24, Núm. 1

  3. New-onset giant cell arteritis following COVID-19 mRNA (BioNTech/Pfizer) vaccine: a double-edged sword?

    Clinical Rheumatology

  4. Prevalence of post-COVID-19 in patients with fibromyalgia: a comparative study with other inflammatory and autoimmune rheumatic diseases

    BMC Musculoskeletal Disorders, Vol. 23, Núm. 1

  5. Ultrasound intima media thickness cut-off values for cranial and extracranial arteries in patients with suspected giant cell arteritis

    Frontiers in Medicine, Vol. 9

2021

  1. Clinical impact of confinement due to the COVID-19 pandemic on patients with fibromyalgia: A cohort study

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3

  2. Radiosynovectomy in routine care: an old tool with modern applications

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

  3. Safety in the use of ultrasound in rheumatology during the COVID-19 Pandemic. Spanish Society of Rheumatology positioning paper

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 284-289

  4. Subclavian artery involvement in patients with giant cell arteritis: do we need a modified Halo Score?

    Clinical Rheumatology, Vol. 40, Núm. 7, pp. 2821-2827

  5. Ultrasound in clinically suspect arthralgia: the role of power Doppler to predict rheumatoid arthritis development

    Arthritis Research and Therapy, Vol. 23, Núm. 1

  6. Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review

    Rheumatology and Therapy, Vol. 8, Núm. 1, pp. 17-40